Prevalence and Epidemiology of HIV Type 1 Drug Resistance among Newly Diagnosed Therapy-Naive Patients in Belgium from 2003 to 2006

• DOI: 10.1089/aid.2007.0212
• Publication Date: 2008-03-07T14:44:49Z
• Authors: Jurgen Vercauteren; Inge Derdelinckx; André Sasse; Marleen Bogaert; Helga Ceunen; Ann De Roo; Stephane De Wit; Koen Deforche; Fedoua Echahidi; Katrien Fransen; Jean-Christophe G...; Patrick Goubau; Elodie Goudeseune; Jean-Cyr Yombi; Patrick Lacor; Corinne Liesnard; Michel Moutschen; Denis Pierard; Roeland Rens; Yoeri Schrooten; Dolores Vaira; Annelies van den ...; Bea van der Gucht; Marc van Ranst; Eric van Wijngaerden; Bernard Vandercam; Marc Vekemans; Chris Verhofstede; Nathan Clumeck; Anne-Mieke Vandamme; Kristel van Laethem
• Keywords: Efavirenz

This study is the first prospective to assess prevalence, epidemiology, and risk factors of HIV-1 drug resistance in newly diagnosed HIV-infected patients Belgium. In January 2003 it was initiated as part pan-European SPREAD program, continued thereafter for four inclusion rounds until December 2006. Epidemiological, clinical, behavioral data were collected using a standardized questionnaire genotypic testing done on sample taken within 6 months diagnosis. Two hundred eighty-five included. The overall prevalence transmitted Belgium 9.5% (27/285, 95% CI: 6.6–13.4). Being infected Belgium, which largely coincided with harboring subtype B virus, found be significantly associated transmission resistance. relatively high rate baseline might jeopardize success line treatment more than 1 out 10 (30/285, 10.5%) viruses did not score fully susceptible one recommended first-line regimens, i.e., zidovudine, lamivudine, efavirenz. Our results support implementation standard care all treatment-naive